



**For Immediate Release
June 4, 2013**

**SUNSHINE BIOPHARMA ANNOUNCES THAT ITS BREAST CANCER DRUG
CANDIDATE, Adva-27a, ALSO DESTROYS PANCREATIC CANCER CELLS**

Montreal, Quebec, Canada -- (MARKETWIRE) -- Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a new IND-Enabling study in which Adva-27a, the Company's flagship oncology drug candidate for breast cancer was found to be effective at killing Pancreatic Cancer Cells in vitro. The study was carried out in the well-established very aggressive Pancreatic Cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of less than 4 micromolar, a pharmacologically very favorable drug concentration. Sunshine Biopharma had previously reported that Adva-27a is capable of effectively killing other aggressive or multidrug resistant cancer cells including Breast Cancer cells (MCF-7/MDR), Small-Cell Lung Cancer cells (H69AR), and Uterine Sarcoma cells (MES-SA/Dx5).

"This brings to four the total number of Aggressive or Multidrug Resistant Cancer types that Adva-27a can destroy. Other chemotherapy drugs are completely ineffective against these cancers", said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "This confirms the general effectiveness of Adva-27a against Aggressive or Multidrug Resistant Cancer", he added.

About Pancreatic Cancer

Pancreatic cancer has an extremely poor prognosis. Most pancreatic cancer patients will die within one year of diagnosis. Cancer of the pancreas is the fourth most common cause of cancer-related deaths in the United States. According to the American Cancer Society, an estimated 45,220 new cases of pancreatic cancer will be diagnosed in the U.S. in 2013. Approximately 95% of pancreatic tumors are of the adenocarcinoma type, arising within the exocrine component of the pancreas where various digestive enzymes are produced. The remaining 5% arise from the islet cells and are classified as neuroendocrine tumors. The islet cells produce important hormones such as insulin, which regulates the sugar levels in the blood. Both types are very aggressive and respond poorly to standard chemotherapy drugs. In contrast to the downward trend in death rates for most major cancer types, such as lung, colorectal, female breast and prostate, death rates due to pancreatic cancer have been slowly increasing in the U.S. over the past decade. This, together with the lack effective therapy, underscores the need for major new drug development efforts to reverse these trends.

About Sunshine Biopharma Inc.

Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma



recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a, which is currently targeted for multidrug resistant cancer.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information Contact:

Camille Sebaaly, CFO

Sunshine Biopharma Inc.

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

www.sunshinebiopharma.com